Quantcast

Latest liver cancer Stories

2014-09-08 12:28:40

- In vivo data support potential clinical benefit of first therapeutic to target a defined subset of liver cancer patients based on genetic profile - CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Blueprint Medicines today announced the presentation of preclinical data investigating BLU-554, a first-in-class selective fibroblast growth factor receptor 4 (FGFR4) inhibitor, for the treatment of patients with hepatocellular carcinoma (HCC). Results demonstrate in vivo efficacy,...

2014-09-08 08:30:50

Highly Attended Celsion-Sponsored Symposium on Current Concepts for Treating Intermediate HCC included: New Paradigm in Staging HCC Patients; Phase III Studies in HCC; and Advances in Image Guided Radiofrequency Ablation LAWRENCEVILLE, N.J., Sept. 8, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's...

2014-09-08 08:30:26

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8(th) International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD,...

2014-09-05 23:00:54

Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone. Data Presented at International Liver Cancer Association Conference. MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with...

2014-09-05 08:23:08

In preclinical studies, CF102 induces hepatocyte proliferation resulting in improved liver status PETACH TIKVA, Israel, Sept. 5, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent...

2014-09-04 08:31:36

ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients LAWRENCEVILLE, N.J., Sept. 4, 2014 /PRNewswire/ -- September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1...

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...

2014-08-25 08:28:14

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity,...

2014-08-14 08:29:11

CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in...

obesity and cancer
2014-08-14 07:24:04

redOrbit Staff & Wire Reports - Your Universe Online Obesity increases a person’s risk of developing 10 of the most common forms of cancer, and is believed to cause an estimated 12,000 additional cases of the disease each year, experts from the London School of Hygiene and Tropical Medicine (LSHTM) and the Farr Institute of Health Informatics claim in a new study. The research, which was published online Thursday in the UK medical journal The Lancet, looked at the medical data of...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'